[{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"TENDU vaccine","moa":"T cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"TENDU Vaccine","moa":"T cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Oslo University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Oslo University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Oslo University Hospital"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"T cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"hTERT specific CD4-helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"hTERT specific CD4-helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Tendu","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Ultimovacs
Details :
UV1 is a universal off-the-shelf therapeutic cancer vaccine designed to induce a specific T cell response against telomerase for the treatment of patients with inoperable advanced or metastatic NSCLC.
Details :
UV1 is a hTERT inhibitor, which is being evaluated in combination with pembrolizumab in patients for the treatment of metastatic or recurrent head and neck cancer.
Details :
UV1, which is a hTERT inhibitor, is being evaluated in Phase II clinical trial studies in combination with keytruda for treating Metastatic or Recurrent Head and Neck Cancer.
Details :
UV1 is an off-the-shelf cancer vaccine designed to induce a specific T cell response against telomerase. It is being evaluated in combination with pembrolizumab for treatment of malignant melanoma..
Details :
Ultimovacs UV1 is an hTERT inhibitor in phase 2 trials with Ipilimumab and Nivolumab for treating unresectable or metastatic malignant melanoma.
Details :
UV1 is a cancer vaccine inducing T cell response against telomerase, evaluated in phase 2 trials with ipilimumab and nivolumab for unresectable malignant pleural mesothelioma.
Details :
UV1 is a cancer vaccine targeting telomerase, under phase 2 trials with ipilimumab and nivolumab for unresectable malignant pleural mesothelioma.
Details :
UV1 is a universal cancer vaccine designed to induce a T-cell response against telomerase, currently in Phase 2 clinical development in combination with nivolumab and ipilimumab for treating melanoma.
Details :
TENDU vaccine is a therapeutic peptide conjugate vaccine, which is under phase 1 clinical development for the treatment of patients with prostate cancer.
Details :
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase, being developed in combination with the checkpoint inhibitors ipilimumab and nivolumab in the treatment of patients with unresectable or metastatic ...
Reset All
